R01AG059421
Project Grant
Overview
Grant Description
Cognitively healthy nonagenarians in the Cross Cohort Collaboration (CCC) - half of all persons who develop clinical dementia become symptomatic after age 85 years, whereas most studies of dementia have focused on younger patients in their 70s.
Compared to dementia beginning at a younger age, dementia in the oldest-old has a more heterogeneous, multifactorial etiology.
Although Alzheimer disease remains important, there are greater contributions from vascular brain injury, systemic disease and dysfunction that indirectly affects the brain, and recently described, poorly understood brain pathologies.
Vascular and lifestyle risk factors may contribute differently to risk of dementia in the oldest-old.
Conversely, it is also important to learn what resilience factors permit persons to remain alive and cognitively normal as nonagenarians.
Studies that enroll persons aged 85+, often lack information from when these individuals were middle-aged.
Longitudinal cohort studies that enrolled participants between ages 45 and 70 years and followed them past age 80 years, till they died or developed dementia, would be ideal study samples, but each such cohort usually has only a small number of participants surviving beyond age 80.
One solution is to combine data across multiple longitudinal studies with harmonizable protocols.
The Cross-Cohort Collaboration Consortium (CCC) was established in 2018, as an offshoot of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium.
The neurology working group within the CCC (led by MPIs Seshadri, Ikram, Dufouil, Debette, Satizabal) brought together 8 cohorts (RF1 AG059421) to study late life dementia.
We now request a renewal of this grant to expand and continue the collaboration.
We will add 5 new cohorts reaching 13 cohorts, to study 102,285 participants, 37,803 with brain MRI, and add a new MPI in Suchy-Dicey who will bring her experience working with AD in American Indians.
We propose the following aims.
Aim 1: To relate various risk factors, systemic illness and MRI markers in midlife (ages 45 to 70) to (A) the risk of late life dementia, and (B) the probability of reaching age 85 (+/- 5) years, alive and dementia free (‘wellderly’).
Aim 2: To assess (A) the impact of multimorbidity examining how persons with two or more chronic conditions differ in life-expectancy and dementia risk and (B) to combine various risk and resilience factors, multimorbidity and MRI measures using artificial intelligence and machine learning to create parsimonious models that predict late-onset dementia and wellderly status.
Aim 3: To examine the biological pathways underlying the observed associations using pathway analyses and structural equation modeling to explore the mediating role of plasma proteins.
The proteins we study will include known biomarkers of amyloid, tau and neurodegeneration (Aβ40 Aβ42, P-Tau181/217, NFL, GFAP) in 37,824 individuals, as well as an array of 3000+ plasma proteins in 38,067 persons (new assays on Olink® explore 3072 + available data) so we can identify previously unsuspected biology using Mendelian randomization methods to examine causality.
Aim 4: We will investigate any effect modification by sex, age, race, ethnicity, urban or rural residence, menopause, APOE genotype on findings from aims 1-3.
We hope to uncover putative drug targets to reduce risk of late life dementia.
Compared to dementia beginning at a younger age, dementia in the oldest-old has a more heterogeneous, multifactorial etiology.
Although Alzheimer disease remains important, there are greater contributions from vascular brain injury, systemic disease and dysfunction that indirectly affects the brain, and recently described, poorly understood brain pathologies.
Vascular and lifestyle risk factors may contribute differently to risk of dementia in the oldest-old.
Conversely, it is also important to learn what resilience factors permit persons to remain alive and cognitively normal as nonagenarians.
Studies that enroll persons aged 85+, often lack information from when these individuals were middle-aged.
Longitudinal cohort studies that enrolled participants between ages 45 and 70 years and followed them past age 80 years, till they died or developed dementia, would be ideal study samples, but each such cohort usually has only a small number of participants surviving beyond age 80.
One solution is to combine data across multiple longitudinal studies with harmonizable protocols.
The Cross-Cohort Collaboration Consortium (CCC) was established in 2018, as an offshoot of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium.
The neurology working group within the CCC (led by MPIs Seshadri, Ikram, Dufouil, Debette, Satizabal) brought together 8 cohorts (RF1 AG059421) to study late life dementia.
We now request a renewal of this grant to expand and continue the collaboration.
We will add 5 new cohorts reaching 13 cohorts, to study 102,285 participants, 37,803 with brain MRI, and add a new MPI in Suchy-Dicey who will bring her experience working with AD in American Indians.
We propose the following aims.
Aim 1: To relate various risk factors, systemic illness and MRI markers in midlife (ages 45 to 70) to (A) the risk of late life dementia, and (B) the probability of reaching age 85 (+/- 5) years, alive and dementia free (‘wellderly’).
Aim 2: To assess (A) the impact of multimorbidity examining how persons with two or more chronic conditions differ in life-expectancy and dementia risk and (B) to combine various risk and resilience factors, multimorbidity and MRI measures using artificial intelligence and machine learning to create parsimonious models that predict late-onset dementia and wellderly status.
Aim 3: To examine the biological pathways underlying the observed associations using pathway analyses and structural equation modeling to explore the mediating role of plasma proteins.
The proteins we study will include known biomarkers of amyloid, tau and neurodegeneration (Aβ40 Aβ42, P-Tau181/217, NFL, GFAP) in 37,824 individuals, as well as an array of 3000+ plasma proteins in 38,067 persons (new assays on Olink® explore 3072 + available data) so we can identify previously unsuspected biology using Mendelian randomization methods to examine causality.
Aim 4: We will investigate any effect modification by sex, age, race, ethnicity, urban or rural residence, menopause, APOE genotype on findings from aims 1-3.
We hope to uncover putative drug targets to reduce risk of late life dementia.
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
San Antonio,
Texas
782293901
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 44% from $3,267,462 to $4,709,204.
The University Of Texas Health Science Center At San Antonio was awarded
Late-Onset Dementia Risk Factors in Midlife Cohorts
Project Grant R01AG059421
worth $4,709,204
from National Institute on Aging in September 2018 with work to be completed primarily in San Antonio Texas United States.
The grant
has a duration of 12 years 4 months and
was awarded through assistance program 93.866 Aging Research.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 3/5/26
Period of Performance
9/1/18
Start Date
1/31/31
End Date
Funding Split
$4.7M
Federal Obligation
$0.0
Non-Federal Obligation
$4.7M
Total Obligated
Activity Timeline
Transaction History
Modifications to R01AG059421
Additional Detail
Award ID FAIN
R01AG059421
SAI Number
R01AG059421-625004788
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
C3KXNLTAAY98
Awardee CAGE
0NJ12
Performance District
TX-20
Senators
John Cornyn
Ted Cruz
Ted Cruz
Modified: 3/5/26